{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:49:29Z","timestamp":1788817769390,"version":"build-2803163510"},"reference-count":54,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chair of Knowledge and Innovation \u201cCaja Rural de Soria\u201d","award":["SO-12-2022"],"award-info":[{"award-number":["SO-12-2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Scleroderma or systemic sclerosis (SSc) is an autoimmune disease affecting the connective tissue, characterized by fibrosis of the skin and internal organs. There is currently no curative treatment available, so therapeutic action is aimed at a symptomatic treatment of the affected organs. The development of biotechnology has made it possible to implement certain biological drugs that could represent a window of opportunity to modulate the evolution and symptomatology of scleroderma with greater efficacy and less toxicity than conventional treatments. This study aimed to review the current evidence critically and systematically on the effects of biological drugs on the pulmonary function, skin disease, and health status of patients afflicted by diffuse cutaneous systemic sclerosis (dcSSc). Three electronic databases (Pubmed, Dialnet, and Cochrane Library Plus) were systematically searched until the cut-off date of October 2022. The review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included original articles in English and Spanish with a controlled trial design, comparing biological drug treatments (tocilizumab, belimumab, riociguat, abatacept, and romilkimab) with a control group. The methodological quality of the studies was assessed using the McMaster quantitative form and the PEDro scale. A total of 383 studies were identified, 6 of them met the established criteria and were included in the present systematic review. A total of 426 patients treated with tocilizumab, belimumab, riociguat, abatacept, and romilkimab were included. The results showed substantial non-significant (p &lt; 0.05) improvement trends after treatment with the biological drugs included in this review for the modified Rodnan Scale Value, Forced Vital Capacity, and Carbon Monoxide Diffusion Test; however, no benefits were shown on the Health Assessment Questionnaire\u2013Disability Index when compared to the control group. Biological drugs, therefore, maybe a new therapeutic strategy for dcSSc and could be recommended as an additional and\/or adjunctive treatment that promotes anti-fibrotic activity. This review could further define the clinical rationale for the use of biologics in the treatment of dcSSc and could provide key details on the study protocol, design, and outcome reporting.<\/jats:p>","DOI":"10.3390\/medicina59020247","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:31:27Z","timestamp":1675053087000},"page":"247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-8896","authenticated-orcid":false,"given":"Diego","family":"Fern\u00e1ndez-L\u00e1zaro","sequence":"first","affiliation":[{"name":"Department of Cellular Biology, Genetics, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42004 Soria, Spain"},{"name":"Neurobiology Research Group, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Iglesias-L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Department of Cellular Biology, Genetics, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42004 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Garrosa","sequence":"additional","affiliation":[{"name":"Neurobiology Research Group, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain"},{"name":"Internal Medicine Department of Soria University Assistance Complex (CAUSO), Santa B\u00e1rbara Hospital, Castile and Leon Health (SACyL), 42005 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1135-2063","authenticated-orcid":false,"given":"David","family":"Jerves Donoso","sequence":"additional","affiliation":[{"name":"Pneumology Department of Soria University Assistance Complex (CAUSO), Santa B\u00e1rbara Hospital, Castile and Leon Health (SACyL), 42003 Soria, Spain"},{"name":"Department of Anatomy and Radiology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42004 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-934X","authenticated-orcid":false,"given":"Eduardo","family":"Guti\u00e9rrez-Abej\u00f3n","sequence":"additional","affiliation":[{"name":"Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain"},{"name":"Pharmacy Directorate, Castile and Leon Health Council, 47007 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Jorge-Finnigan","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Radiology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42004 Soria, Spain"},{"name":"Dermatology Department of Soria University Assistance Complex (CAUSO), Santa B\u00e1rbara Hospital, Castile and Leon Health (SACyL), 42005 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2013.01.010","article-title":"Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies","volume":"31","author":"Fett","year":"2013","journal-title":"Clin. Dermatol."},{"key":"ref_2","first-page":"109","article-title":"Scleroderma-related interstitial lung disease","volume":"22","author":"Suliman","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3899\/jrheum.151018","article-title":"Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study","volume":"43","author":"Smith","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1136\/annrheumdis-2014-205528","article-title":"Evaluation of blood perfusion by laser speckle contrast analysis in different areas of hands and face in patients with systemic sclerosis","volume":"73","author":"Sulli","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","first-page":"1448","article-title":"Esclerodermia","volume":"12","author":"Carreira","year":"2017","journal-title":"Med.-Programa Form."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2004.08.009","article-title":"Severe gastrointestinal involvement in systemic sclerosis: Report of five cases and review of the literature","volume":"34","author":"Jaovisidha","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: The High-Dose Versus Low-Dose D-Penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s12325-022-02078-5","article-title":"Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Scle-rosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases","volume":"39","author":"Kuwana","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s13075-021-02672-y","article-title":"Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality","volume":"23","author":"Porel","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_12","first-page":"89","article-title":"Clinical and epidemiological differences between men and women with systemic sclerosis: A study in a Spanish systemic sclerosis cohort and literature review","volume":"35","author":"Freire","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1002\/art.39765","article-title":"Brief Report: HLA-DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis","volume":"68","author":"Stevens","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"587773","DOI":"10.3389\/fmed.2020.587773","article-title":"Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification","volume":"7","author":"Yang","year":"2020","journal-title":"Front. Med."},{"key":"ref_15","first-page":"454","article-title":"Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis","volume":"70","author":"Gourh","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","first-page":"2737","article-title":"Classification Criteria for Systemic Sclerosis: An ACR-EULAR Collaborative Initiative","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Utsunomiya, A., Oyama, N., and Hasegawa, M. (2020). Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113388"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rutka, K., Garkowski, A., Karaszewska, K., and \u0141ebkowska, U. (2021). Imaging in Diagnosis of Systemic Sclerosis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020248"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.amjms.2022.02.014","article-title":"Assessment of kidney involvement in systemic sclerosis: From scleroderma renal crisis to subclinical renal vasculopathy","volume":"364","author":"Gigante","year":"2022","journal-title":"Am. J. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1080\/14656566.2020.1793960","article-title":"An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis","volume":"21","author":"McMahan","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"The Scleroderma Algorithm Group Treatment Algorithms for Systemic Sclerosis According to Experts","volume":"70","author":"Codina","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103168","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: A systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_23","unstructured":"AseBio (2022, December 13). Innovative Biological Medicines and Biosimilars. Available online: https:\/\/www.asebio.com\/areas-de-trabajo\/salud\/medicamentos-biologicos-biosimilares."},{"key":"ref_24","unstructured":"European Medicines Agency (2022, December 15). Information Guide for Healthcare Professionals Produced Jointly by the European Medicines Agency and the European Commission. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_es.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2397198318758607","article-title":"Kidney involvement in systemic sclerosis: From pathogenesis to treatment","volume":"3","author":"Bruni","year":"2018","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.095299","article-title":"EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Avouac","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","unstructured":"Law, M., Stewart, C., Pollock, N., Letts, L., Bosch, J., and Westmorland, M. (1998). Guidelines for Critical Review of Qualitative Studies, McMaster University Occupational Therapy Evidence-Based Practice Research Group."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/ptj\/83.8.713","article-title":"Reliability of the PEDro Scale for Rating Quality of Randomized Controlled Trials","volume":"83","author":"Maher","year":"2003","journal-title":"Phys. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): Randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/14397595.2018.1452178","article-title":"Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy","volume":"29","author":"Shima","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Foti, R., De Pasquale, R., Bosco, Y.D., Visalli, E., Amato, G., Gangemi, P., Foti, R., and Ramondetta, A. (2021). Clinical and Histopathological Features of Scleroderma-like Disorders: An Update. Medicina, 57.","DOI":"10.3390\/medicina57111275"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","article-title":"Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis","volume":"18","author":"Fang","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Shima, Y. (2021). Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy. Cells, 10.","DOI":"10.3390\/cells10051104"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: Insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2019.07.010","article-title":"Management of cutaneous manifestations of lupus erythematosus: A systematic review","volume":"50","author":"Fairley","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.cyto.2011.08.030","article-title":"Role of IL-13 in systemic sclerosis","volume":"56","author":"Fuschiotti","year":"2011","journal-title":"Cytokine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1699-258X(06)73102-3","article-title":"Pulmonary involvement in systemic sclerosis. Alveolitis, fibrosis and pulmonary arterial hypertension","volume":"2","author":"Navarro","year":"2006","journal-title":"Reumatol. Cl\u00ednica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/1744666X.2020.1668269","article-title":"Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease","volume":"15","author":"Distler","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Erre, G.L., Sebastiani, M., Fenu, M.A., Zinellu, A., Floris, A., Cavagna, L., Renzoni, E., Manfredi, A., Passiu, G., and Woodman, R.J. (2020). Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082560"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14397595.2019.1640343","article-title":"Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis","volume":"30","author":"Zheng","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: A multicentre retrospective study","volume":"50","author":"Manfredi","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_47","first-page":"1","article-title":"Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: An analysis from the EUSTAR database","volume":"22","author":"Allanore","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/acr.20598","article-title":"Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician- and Patient-Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/art.21084","article-title":"The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: An evaluation of their measurement properties","volume":"53","author":"Johnson","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1759720X17690474","article-title":"Belimumab in systemic lupus erythematosus (SLE): Evidence-to-date and clinical usefulness","volume":"9","author":"Isenberg","year":"2017","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_51","unstructured":"ClinicalTrialsgov (2023, January 14). Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03844061."},{"key":"ref_52","unstructured":"Good Clinical Practice (2023, January 15). Clinical trials on Systemic Scleroderma: Diffuse Scleroderma: Systemic Scleroderma: Riociguat: Riociguat (Adempas, BAY63-2521). Clinical Trials Registry. Available online: https:\/\/ichgcp.net\/es\/clinical-trials-registry\/NCT02283762."},{"key":"ref_53","first-page":"1","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_54","unstructured":"(2023, January 15). European Medicines Agency. EU\/3\/19\/2246. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3192246."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:29Z","timestamp":1760120249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["medicina59020247"],"URL":"https:\/\/doi.org\/10.3390\/medicina59020247","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}